Skip to main content

Table 1 Baseline profile of EndoAfrica-NWU participants

From: Vascular function and cardiovascular risk in a HIV infected and HIV free cohort of African ancestry: baseline profile, rationale and methods of the longitudinal EndoAfrica-NWU study

 

HIV infected

n = 278

HIV uninfected

n = 104

P-value

Men, n (%)

74/278 (26.6)

32/104 (30.8)

0.42

Age (years)

42.7 ± 9.13

38.9 ± 11.7

0.004

Employed, n (%)

58/275 (21.1)

42/104 (40.4)

< 0.001

Education, n (%)

  

0.037

None

6/274 (2.19)

3/104 (2.89)

 

Primary

62/274 (22.6)

24/104 (23.1)

 

Secondary

187/274 (68.3)

60/104 (57.7)

 

Tertiary

19/274 (6.93)

17/104 (16.4)

 

Anthropometry

 Waist circumference (cm)

84.7 ± 13.5

87.2 ± 15.6

0.15

 Body mass index (kg/m2)

26.2 ± 7.19

28.5 ± 8.24

0.013

Cardiovascular profile

 Hypertensive, n (%) a

90/278 (32.4)

44/104 (42.3)

0.070

 Systolic blood pressure (mmHg)

120 ± 21.6

123 ± 18.8

0.32

 Diastolic blood pressure (mmHg)

84 ± 13.1

87 ± 14.8

0.052

 Heart rate (beats/min)

72 ± 13.0

71 ± 14.0

0.50

 Flow-mediated dilation (%) b

7.44 (6.77;8.12)

7.23 (6.10;8.36)

0.75

 Pulse wave velocity (m/s) b

7.81 (7.66;7.97)

7.72 (7.46;7.98)

0.54

Basic biochemical variables

 Total cholesterol (mmol/L)

2.88 (1.71;4.42)

2.71 (1.80;4.09)

0.047

 HDL (mmol/L)

1.00 (0.51;1.94)

0.89 (0.53;1.85)

0.010

 LDL (mmol/L)

1.62 (0.78;2.86)

1.60 (0.86;3.07)

0.82

 Triglycerides (mmol/L)

0.78 (0.35;2.16)

0.68 (0.30;1.93)

0.040

 Glucose (mmol/L)

3.62 (2.75;5.11)

3.66 (2.67;7.61)

0.70

 Glycated haemoglobin (%)

5.46 (4.80;6.53)

5.74 (4.90;10.5)

0.017

 C-reactive protein (mg/L)

2.48 (0.25;16.1)

1.85 (0.13;20.1)

0.063

 Gamma-glutamyltransferase (U/L)

51.2 (11.1;419)

22.3 (6.92;172)

< 0.001

 eGFR (ml/min/1.73m2)

118 (92.5;147)

122 (97.9;151)

0.055

Health behaviours

 Tobacco use, n (%)

159/276 (57.6)

44/104 (42.3)

0.008

 Alcohol use, n (%)

185/275 (67.3)

61/104 (58.7)

0.12

 Physically active, n (%)

241/276 (87.3)

89/104 (85.6)

0.65

HIV related variables

 Duration of HIV > 5 years, n (%)

171/276 (62.0)

–

–

 CD4 count (cells/μL)

417 (68.8;1121)

–

–

 Viral load (copies/mL)

125 (10.0;93,433)

–

–

Medication use

 Antiretroviral therapy, n (%)

Never

9/278 (3.23)

–

–

Defaulted

47/278 (16.9)

–

–

Currently

222/278 (79.9)

–

–

Duration of ART > 5 years, n (%)

124/265 (46.8)

–

–

Anti-hypertensive, n (%)

50/278 (18.0)

26/104 (25.0)

0.13

Statins, n (%)

6/278 (2.16)

6/104 (5.77)

0.072

Anti-diabetic, n (%)

2/278 (0.72)

5/104 (4.81)

0.008

Anti-inflammatory, n (%)

0/278 (0.00)

1/104 (0.96)

0.10

  1. Data are expressed as arithmetic mean ± standard deviation, geometric mean (5th and 95th percentiles) or a percentage of N
  2. HIV human immunodeficiency virus, HDL high-density lipoprotein cholesterol, LDL low-density lipoprotein cholesterol, eGFR estimated glomerular filtration rate, ART antiretroviral therapy
  3. aSystolic blood pressure ≥ 140 mm Hg and/or diastolic blood pressure ≥ 90 mm Hg and/or use of antihypertensive medication
  4. bAdjusted for systolic blood pressure and age, data expressed as mean (95%CI)
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us